Medical Prognosis Institute A-S News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

04.11.20	Allarity Therapeutics Hires New Chief Financial Officer (GlobeNewswire)
26.10.20	Allarity Therapeutics Gains Allowance from U.S. Patent and Trademark Office for New DRP® Biomarker Patents (GlobeNewswire)
23.10.20	Allarity Therapeutics Provides Update on Dovitinib Program (GlobeNewswire)
09.10.20	Allarity Therapeutics will trade under new short name ALLR starting on 12 October 2020 (GlobeNewswire)
07.10.20	Press Release Allarity Therapeutics Shareholders Approve Company Name Change and Board Appointments (GlobeNewswire)
06.10.20	Press Release Oncology Venture calls third investment tranche under its share subscription agreement with Global Corporate Finance (GlobeNewswire)
06.10.20	Press Release Oncology Venture A/S Issues 1,619,912 Shares in Exchange for Previously Annulled Warrants (GlobeNewswire)
21.09.20	Notice to Convene an Extraordinary General Meeting (GlobeNewswire)
21.09.20	Press Release Oncology Venture Plans Name Change to Allarity Therapeutics and Board Restructuring to Align with Current Company Strategy (GlobeNewswire)
28.08.20	Press Release Oncology Venture Publishes Interim Report for the Period January – June 2020 (GlobeNewswire)
26.08.20	Press Release Oncology Venture’s Novel PARP Inhibitor Stenoparib (formerly 2X-121) Shows Anti-Viral Activity Against Coronavirus in Pre-Clinical Studies (GlobeNewswire)
21.08.20	Press Release Oncology Venture will offer new shares in exchange for previously annulled warrants as part of clean-up of remaining obligations incurred prior to former management departure (GlobeNewswire)
21.08.20	Press Release Oncology Venture calls second investment tranche under its share subscription agreement and issues 5,980,020 shares to Global Corporate Finance (GlobeNewswire)
14.08.20	Press Release Oncology Venture issues 1,893,939 shares to Negma Group LTD and Park Partners GP and thereby all outstanding convertible loan notes are converted (GlobeNewswire)
14.07.20	Press Release Oncology Venture is issuing 2,255,639 shares under its existing convertible loan note agreement with Negma Group LTD and Park Partners GP (GlobeNewswire)
13.07.20	Press release Oncology Venture acquires full ownership of its PARP inhibitor (2X-121) program (GlobeNewswire)
30.06.20	Press Release Oncology Venture is issuing 1,574,803 shares under its existing convertible loan note agreement with Negma Group LTD and Park Partners GP (GlobeNewswire)
29.06.20	Press release Oncology Venture signs agreement to out-license two pipeline assets as part of prioritized portfolio strategy (GlobeNewswire)
18.06.20	Press release Oncology Venture is issuing 5,177,584 shares under its share subscription agreement with Global Corporate Finance (GlobeNewswire)
11.06.20	Press Release Oncology Venture terminates agreement with liquidity provider (GlobeNewswire)
10.06.20	Press Release Oncology Venture is issuing 2,255,639 shares under its convertible note agreement with Negma Group LTD and Park Partners GB (GlobeNewswire)
09.06.20	Press Release Oncology Venture calls first investment tranche of SEK 10 million under its share subscription agreement with Global Corporate Finance (GlobeNewswire)
09.06.20	Press Release Oncology Venture is issuing 751,879 shares under its convertible note agreement with Negma Group LTD and Park Partners GB (GlobeNewswire)
08.06.20	Press release Oncology Venture acquires full control of Dovitinib program (GlobeNewswire)
29.05.20	Company Announcement Oncology Venture Publishes Q1 2020 Report for the Period January – March 2020 (GlobeNewswire)
07.05.20	Press release Oncology Venture issues 1,952,475 new shares in connection with debt conversions (GlobeNewswire)
06.05.20	Press release Oncology Venture secures a US $5 million (50 million SEK) equity investment from a new US based investor (GlobeNewswire)
22.04.20	Minutes from Annual General Meeting 2020 (GlobeNewswire)
22.04.20	Press release Oncology Venture to test activity of its PARP inhibitor, 2X-121, as a potential therapy for Coronavirus (GlobeNewswire)
17.04.20	Press Release Oncology Venture is issuing 925,925 shares under its convertible note agreement with Negma Group LTD and Park Partners GB (GlobeNewswire)
07.04.20	Notice to convene Annual General Meeting 2020 (GlobeNewswire)
03.04.20	Press Release Oncology Venture draws down the first tranche under its Convertible note agreement with Negma Group LTD and Park Partners GB (GlobeNewswire)
31.03.20	Press Release Oncology Venture publishes the Annual Report for 2019 (GlobeNewswire)
31.03.20	Press release Oncology Venture establishes a convertible note program of 100 million SEK (GlobeNewswire)
20.03.20	Press release Oncology Venture receives feedback from U.S. FDA on potential approval pathway for Dovitinib. (GlobeNewswire)
26.02.20	Press release Oncology Venture to present on its DRP® technology at upcoming Google Cloud NEXT Conference. (GlobeNewswire)
24.02.20	Press release Oncology Venture & Alpha Blue Ocean mutually terminates agreement with EHGO as part of final financing (GlobeNewswire)
31.01.20	Press release Oncology Venture – First day of trading in TO2 warrants (GlobeNewswire)
13.01.20	Press release Oncology Venture to present a poster at upcoming PARP & DDR Inhibitor Summit on clinical development of 2X-121 (GlobeNewswire)
10.01.20	Press release Oncology Venture issues 287,500 new shares in connection with a debt conversion (GlobeNewswire)
12.12.19	Press release Swedish financier Mats Gabrielsson becomes major shareholder in Oncology Venture (GlobeNewswire)
05.12.19	Press release Oncology Venture rights issue fully subscribed (GlobeNewswire)
29.11.19	Company Announcement Oncology Venture publishes Interim Report for the period January – September 2019 (GlobeNewswire)
13.11.19	Oncology Venture advancing towards next milestone in its clinical development of IXEMPRA®. (GlobeNewswire)
12.11.19	Oncology Venture can inform that the last trading day of the Subscription Rights is now 19 November 2019, following the extension of subscription period until the 21 November of the current rights iss (GlobeNewswire)
12.11.19	Oncology Venture extends the subscription period of the current rights issue (GlobeNewswire)
12.11.19	Oncology Venture advancing towards next milestone in its clinical development of 2X-121. (GlobeNewswire)
12.11.19	Oncology Venture reaches new development milestone with Dovitinib. (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Givaudan	4’040.00	1.71 %	K V
Geberit	547.80	1.59 %	K V
Part Grp Hldg	1’297.00	1.49 %	K V
ABB	51.94	1.29 %	K V
Swiss Life Hldg	691.80	1.26 %	K V
Zurich Insur Gr	548.00	-0.18 %	K V
Kuehne+Nagel Int	210.90	-0.33 %	K V
Swiss Re	128.20	-0.66 %	K V
Sonova Hldg	293.00	-0.85 %	K V
Novartis	87.94	-0.92 %	K V

Nachrichten zu Medical Prognosis Institute A-S

Aktien Top/Flop

Meistgelesene Nachrichten